|
Highlights of research findings
COMPARATIVE STUDY OF POPULAR PENIS TRACTION DEVICES--
CLICK HERE |
Size Genetics - Rated #1
|
|
Penile enlargement without surgery with the SizeGenetics Device
Scientific Research presented in the 1st Virtual Sexology
and Hispanoamerican Sexual Education Congress (February -2001)
Dr. Eduardo A. Gomez de Diego 1998 Andrology Services ,Andromedical
Clinic, Madrid (Spain)
1.
Introduction:
When the human tissues are submitted to a force
of traction, they react by increasing in size.
The principle of traction is applied in modern medicine, for the generation
of new tissue to cover burn wounds or areas of hair loss ( placing
a tissular expander underneath the normal skin ) or for the lengthening
of bones.
In other cultures this principle is applied to lengthen different
parts of the body like the Giraffe Women of the Paduang tribe in Birmania
; or the lengthening of the lips in certain African tribes of Africa
that use wood to create traction; and in India where they hang stones
on the penis of men as a form of penitence with the resulting enlargement
of the organ.
Based on this principle of external traction the SizeGenetics®
was designed . It is able to exhort a gradual traction force of 600
to 1500 grams.
The device consists of a plastic ring, where the penis is introduced
and from where 2 dynamic metalic rods that originate the traction.
In the superior part there is a plastic support where a silicone band
holds the glans in place.
Based on our clinical experience the traction
device yields the following results:
-
An increase in the length of the penis in erection
and flaccidity.
-
An increase in the perimeter of the penis in erection
and flaccidity.
-
This results will be analyzed statistically to be
verified and quantified
2.
Materials and Methods
Number of patients: 37 patients, ages between 22 and 60 years
of age. These men proceed from different cities in Spain.
Selection of patients: patients included were healthy men with
normal erection capabilities and without penile surgeries. Patients
with penile or other diseases where excluded from the studies.
Traction device: The SizeGenetics®, German penile traction device.
Traction Force: 600 gr during 1st month, 900 gr during 2nd month,
1100 gr durante 3th and 4th mes, and 1200 gr during 5th y 6th month.
Usage period: 10 hours a day, during every day of the month for
a period of 3-6 months.
3. Results
3.1.- INCREASE IN LENGTH IN ERECTION:
-
The average increase in the length of the penis
in erection by month is of 0.4726 cm. The standard deviation is
of 0.1329 cm. The confidential interval of 95% is of [0.4283 ; 0.5169]
which indicates a minimal gain in the population of 0.4283 cm/month.
-
Regression line is:
DL erec = - 0.327 + 0.562 x t
This calculation will allow us to estimate the increase in length
of the penis in erection, based on the months of use of the device.
There is a 57.7% variance in the increment in longitude, which is
explained by the variance in the duration of treatment ( R2= 0.577
). The other 42.3% is due to other differences innate to each individual
and not relative to the duration of the treatment
3.2.- INCREMENT IN LENGTH IN THE FLACCID STATE
-
The increment in length in the flaccid state is
relative to the time of usage of the device. Such an increment is
linear as shown in the graph. The longer the device is used, the
greater the increase in length. The coefficient of the linear correlation
between the time of usage and the increment in longitude in the
flaccid state is of 0.725 ( p=0.000 ).
-
The average monthly increment in longitude of the
penis in the flaccid state is 0.4834 cm and the typical deviation
is 0.1983 cm. The confidence interval of 95% is of [0.4173 ; 0.5495]
and indicates a minimum increase in the population of 0.4173 cm/month.
-
Regression line is:
DL flac = - 1.300 + 0.840 x t
This calculation allows us to estimate the increment in longitude
in the flaccid state based on the months in which the device is
used. There is a 52.5% variance in the increment in longitud which
is explained by the variance of the duration of treatment ( R2=
0.525 ). The other 47.5% is due to other differences innates to
the individual and not relative to the duration of the treatment.
3.3.- VARIABILITY:
-
The variability in the increment in longitude in
erection is different from that of flaccidity, being the difference
in variance significant ( p= 0.003 ) which indicates a greater dispersion
of the increases in length during flaccidity than in erection.
3.4.- THE INCREMENT IN LONGITUDE DOES NOT
DEPEND ON THE AGE:
-
A very interesting result was that the increment
in longitude does not depend on the age of the patient, since the
coefficient of the linear correlation is not significant ( r=0.008,
p=0.961). In other words, the age of the patient does not effect
the increment in longitude.
-
-
3.7.- LONGITUDE INCREASE IN ERECTION STATE DEPENDING ON
USE:
-
Dividing the population studied in four sub groups
depending on the usage time of the SizeGenetics®. we obtain the following results.
Three months usage:
The median longitude increment in erection state was 1.4118, obtaining
a median growth of 10.5580% over the initial longitude. The confidence
interval of 95% of the studied population was ( 1.1522; 1.6713)
which shows a median minimal growth of 1.1522 cm in three months.
Four months usage:
The median longitude increment in erection state was 1.8462, obtaining
a median growth of 14.1113% over the initial longitude. The confidence
interval of 95% of the studied population was(1.5809; 2.1114) which
shows a median minimal growth of 1.5809 cm in four months.
Five months usage:
The median longitude increment in erection state was 2.2750, obtaining
a median growth of 16.6303% over the initial longitude. The confidence
interval of 95% of the population studied was (1.7656; 2.7844) which
shows a median minimal growth of 1.7656 cm in four months.
Six months usage:
The median longitude increment in erection state was 3.3333, obtaining
a median growth of 27.5% over the initial longitude. The confidential
interval of 95% of the population studied was (2.8162; 3.8504) which
shows a median minimal growth of 2.8162 cm in six months.
The samples corresponding to five and six months are very small
which makes small intervals and less reliable.
3.8.- DISTRIBUTION:
-
Although the variables considered in the population
are not normal, the median samples, have normal distribution since
the amount of the sample is greater than 20.
3.9.- ABBREVIATIONS:
-
|
Inc-Long-Erec
|
Longitude increment in erection
state |
|
DL
erec
|
Change in Longitude increment
in erection state |
|
I.L.ERT
|
Longitude increment in erection
as a function of the time variable |
|
I.L.FLAC
|
Longitude increment in flaccid
state |
|
DL
flac
|
Change in Longitude increment
in flaccid state |
|
I.L.FLT
|
Longitude increment in flaccid
state in function of time |
|
Inc-Long-Erec
|
Longitude increment in erection
state |
|
%
I Long-Erec
|
Longitude increment percentage
in erection state. |
4.
Conclusions
- The use of the German traction device ( SizeGenetics® ) will increase the length
of the penis, both in the erectile and flaccid state.
- The increase in length, both in and flaccidity, is directly
proportional to the time of use.
- The increase in length both in erection and flaccidity, does
not depend on the natural size of the patient.
- The average growth in length of the penis in cm/month in 95%
of the patients was between 0.4283 and 0.5163 in erection, and
between 0.4173 and 0.5495 in flaccidity.
- The increments of change in length of the penis in erection
are more uniform than those in flaccidity which tend to be more
disparate .
- The increment of change in the length of the penis in erection
is not relative to the age of the patient.
- The use of the penile traction device will increase the perimeter
of the penis, both in erection and flaccidity.
- The average growth in perimeter in cm/month in 95% of the patients
was between 0.6111 and 1.0200 in erection, and between 0.6386
and 1.0425 in flaccidity. Treatment was 3-6 months duration.
5.
Anex
PATIENT RESULTS (Using the SizeGenetics®):
-
| Nombre
|
Edad |
Inicio |
L-Erec1 |
L-Flac1 |
P-Erec1 |
P-Flac1 |
Meses |
L-Erec2 |
L-Flac2 |
P-Erec2 |
P-Flac2 |
| LAA |
60 |
15.1.98
|
12.0 |
8.0 |
12.0 |
10.0 |
3.0 |
13.5 |
9.0 |
13.5 |
10.5 |
| EAG |
37 |
30.1.98
|
14.5 |
8.0 |
12.0 |
8.5 |
4.0 |
16.5 |
9.5 |
13.0 |
10.5 |
| VA |
27 |
26.11.97
|
16.3 |
10.4 |
13.9 |
10.1 |
3.0 |
17.8 |
12.5 |
14.5 |
11.5 |
| EAA |
46 |
15.3.98
|
14.5 |
10.5 |
12.0 |
10.0 |
6.0 |
17.6 |
15.7 |
13.2 |
11.2 |
| JBV |
25 |
27.3.98
|
15.0 |
8.0 |
13.0 |
9.0 |
3.0 |
16.6 |
9.5 |
13.3 |
10.5 |
| ABB |
39 |
29.6.98
|
14.0 |
11.0 |
13.0 |
11.0 |
3.0 |
15.5 |
12.5 |
14.0 |
12.0 |
| CBG |
37 |
19.1.98
|
12.5 |
6.0 |
12.0 |
9.0 |
4.0 |
14.0 |
8.8 |
12.5 |
9.4 |
| JBL |
25 |
7.5.98
|
13.7 |
9.0 |
11.5 |
10.0 |
4.0 |
16.3 |
11.5 |
13.5 |
12.0 |
| JCB |
27 |
19.11.97
|
13.0 |
8.0 |
14.5 |
12.0 |
6.0 |
16.4 |
11.1 |
14.2 |
12.2 |
| JJCA |
33 |
1.6.98
|
10.5 |
4.9 |
11.0 |
9.5 |
3.0 |
12.0 |
5.5 |
11.5 |
9.5 |
| JCA |
32 |
4.2.98
|
14.0 |
10.0 |
10.0 |
9.0 |
4.0 |
15.9 |
12.0 |
12.2 |
10.5 |
| ODV |
25 |
4.3.98
|
16.5 |
9.5 |
13.0 |
9.7 |
3.0 |
18.0 |
11.0 |
13.3 |
10.0 |
| PDS |
22 |
10.6.98
|
14.4 |
8.3 |
11.0 |
7.8 |
3.0 |
15.8 |
9.0 |
11.6 |
8.3 |
| AGM |
41 |
26.11.98
|
13.0 |
9.0 |
11.0 |
10.0 |
4.0 |
15.0 |
9.5 |
11.0 |
10.0 |
| MGF |
32 |
29.9.97
|
12.5 |
5.5 |
12.5 |
10.0 |
4.0 |
14.5 |
8.0 |
13.0 |
10.0 |
| AHM |
44 |
5.3.98
|
11.5 |
8.0 |
13.0 |
12.0 |
3.0 |
13.0 |
9.5 |
14.0 |
12.0 |
| AAMP |
37 |
12.3.98
|
12.7 |
7.0 |
10.5 |
7.5 |
3.0 |
14.0 |
9.0 |
11.0 |
9.0 |
| JLMO |
34 |
30.1.98
|
14.8 |
11.0 |
11.0 |
9.3 |
4.0 |
15.8 |
11.0 |
12.7 |
9.3 |
| JAMV |
41 |
28.7.97
|
17.0 |
10.0 |
14.0 |
12.5 |
5.0 |
19.6 |
12.3 |
15.0 |
13.5 |
| FOR |
8% |
9.11.97
|
12.5 |
7.0 |
10.0 |
9.0 |
5.0 |
14.5 |
11.0 |
11.0 |
10.5 |
| ROM |
28 |
12.11.97
|
16.0 |
8.5 |
13.0 |
9.0 |
5.0 |
18.0 |
12.5 |
13.5 |
10.5 |
| JPC |
33 |
16.1.98
|
13.7 |
7.2 |
12.3 |
10.1 |
3.0 |
16.7 |
8.7 |
13.1 |
10.9 |
| JAPG |
29 |
4.11.97
|
10.0 |
8.0 |
12.0 |
10.0 |
6.0 |
13.5 |
11.5 |
13.0 |
11.0 |
| FPR |
8% |
20.3.98
|
10.5 |
7.0 |
12.0 |
10.0 |
3.0 |
11.3 |
7.3 |
12.7 |
10.0 |
| JPF |
42 |
23.3.98
|
13.0 |
7.0 |
13.0 |
10.0 |
3.0 |
14.5 |
8.5 |
13.0 |
10.5 |
| AJRF |
26 |
28.11.97
|
14.0 |
9.0 |
13.0 |
9.0 |
4.0 |
16.0 |
10.7 |
13.0 |
10.0 |
| ARR |
58 |
7.10.97
|
11.0 |
7.0 |
11.0 |
9.0 |
3.0 |
12.0 |
8.0 |
12.0 |
10.0 |
| RRG |
25 |
25.11.97
|
14.5 |
11.0 |
11.0 |
10.0 |
3.0 |
15.0 |
12.4 |
11.7 |
10.8 |
| CSM |
35 |
24.2.98
|
15.0 |
9.0 |
11.0 |
9.0 |
3.0 |
16.5 |
11.0 |
12.0 |
10.0 |
| ASE |
35 |
20.3.98
|
12.5 |
7.5 |
11.5 |
9.0 |
4.0 |
14.5 |
9.5 |
12.5 |
10.5 |
| ASPA |
42 |
7.11.97
|
14.0 |
7.5 |
12.0 |
9.0 |
4.0 |
16.0 |
9.5 |
13.0 |
10.5 |
| SSF |
27 |
15.8.97
|
14.5 |
7.0 |
14.5 |
8.0 |
3.0 |
15.9 |
8.0 |
15.0 |
8.7 |
| ISB |
22 |
23.9.97
|
11.5 |
7.5 |
11.0 |
9.5 |
4.0 |
13.5 |
10.2 |
11.3 |
10.3 |
| FT |
53 |
19.11.97
|
14.5 |
10.0 |
13.0 |
10.0 |
3.0 |
16.0 |
11.5 |
13.5 |
10.5 |
| EVC |
24 |
29.12.97
|
11.0 |
7.0 |
11.5 |
9.0 |
5.0 |
13.5 |
9.0 |
12.5 |
10.5 |
| PV |
33 |
8.10.97
|
12.0 |
8.5 |
15.5 |
13.0 |
4.0 |
13.0 |
9.5 |
16.0 |
13.0 |
| JSVS |
32 |
24.1.98
|
12.0 |
6.0 |
10.5 |
9.0 |
4.0 |
14.0 |
8.5 |
12.5 |
9.5 |
L-Erec1 = Length
in Erection initial
L-Flac1 = Length in Flaccidity inicial
P-Erec1 = Perimeter in Erection initial
P-Flac1 = Perimeter in Flaccidity inicial
L-Erec2 = Length in Erection final
L-Flac2 = Length in Flaccidity final
P-Erec2 = Perimeter in Erection final
P-Flac2 = Perimeter in Flaccidity final
[ Visit
Size Genetics Now ]
[ Compare Size Genetics
with other Enlargement Devices ]
|